Latest News

  • Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis Read More
  • Statement by Richard Pops, Chairman and CEO of Alkermes on the Annual CDC Report on Drug Overdose Deaths and Suicide Mortality in the United States Read More
  • Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia Read More

Investors

Working at Alkermes